A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen

Cell Cycle

Volumn 10, Issue 6, 2011, Pages 956-962

  Lehn, Sophie ^a,b   Fernö, Mårten ^c   Jirström, Karin ^a   Rydén, Lisa ^c   Landberg, Göran ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Endocrine resistance; Predictive marker; RB; Tamoxifen

Indexed keywords

RETINOBLASTOMA PROTEIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREMENOPAUSE; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION;

ANIMALIA;

EID: 79952668699     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.6.15074     Document Type: Article

References (29)

1. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-95. (Pubitemid 32204552)
2. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1:222-31. (Pubitemid 33741897)
3. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996; 69:247-53. (Pubitemid 26298285)
4. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996; 69:92-9.
5. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995; 11:885-91.
6. Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle 2007; 6:667-71. (Pubitemid 46535677)
7. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147:545-60.
8. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12. (Pubitemid 41039110)
9. T'Ang A, Varley JM, Chakraborty S, Murphree AL, Fung YK. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 1988; 242:263-6.
10. Anderson JJ, Tiniakos DG, McIntosh GG, Autzen P, Henry JA, Thomas MD, et al. Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues. J Pathol 1996; 180:65-70. (Pubitemid 26348893)
11. Barbareschi M, Pelosio P, Caffo O, Buttitta F, Pellegrini S, Barbazza R, et al. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer 1997; 74:171-4. (Pubitemid 27234505)
12. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 1998; 79:71-5. (Pubitemid 28157730)
13. Jares P, Rey MJ, Fernandez PL, Campo E, Nadal A, Munoz M, et al. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. J Pathol 1997; 182:160-6. (Pubitemid 27287836)
14. Waltersson MA, Askmalm MS, Nordenskjold B, Fornander T, Skoog L, Stal O. Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer. Int J Oncol 2009; 34:441-8.
15. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007; 117:218-28. (Pubitemid 46048468)
16. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631-43.
17. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-30.
18. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009; 7:511-22.
19. Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G. G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Tr 1999; 56:105-12. (Pubitemid 29494828)
20. Loden M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H, Landberg G. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002; 21:4680-90. (Pubitemid 34833145)
21. Nielsen NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 1997; 14:295-304. (Pubitemid 27073084)
22. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 1996; 271:8313-20. (Pubitemid 26108665)
23. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2010; 9:4153-63.
24. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K. Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. Eur J Cancer 1995; 31:329-33.
25. Ceccarelli C, Santini D, Chieco P, Taffurelli M, Gamberini M, Pileri SA, Marrano D. Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile. J Clin Pathol 1998; 51:818-24. (Pubitemid 28530844)
26. Derenzini M, Donati G, Mazzini G, Montanaro L, Vici M, Ceccarelli C, et al. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin Cancer Res 2008; 14:2199-209. (Pubitemid 351551133)
27. Ryden L, Jonsson PE, Chebil G, Dufmats M, Ferno M, Jirstrom K, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005; 41:256-64. (Pubitemid 40136540)
28. Berglund P, Stighall M, Jirstrom K, Ryden L, Ferno M, Nordenskjold B, Landberg G. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern. J Clin Pathol 2008; 61:184-91. (Pubitemid 351218878)
29. Jirstrom K, Ryden L, Anagnostaki L, Nordenskjold B, Stal O, Thorstenson S, et al. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 2005; 58:1135-42. (Pubitemid 41566455)